ag-1296 has been researched along with Acute Myelogenous Leukemia in 6 studies
6,7-dimethoxy-3-phenylquinoxaline: ATP-competitive inhibitor of receptor kinase
| Excerpt | Relevance | Reference |
|---|---|---|
| "Flt3-ITD+ acute myeloid leukemia (AML) blasts from patients invariably generated early AG1295-sensitive CAs in MS-5 cocultures, further validating the phenotype observed in transduced CD34+ cells." | 1.33 | Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis. ( Chung, KY; Dorn, DC; Moore, MA; Morrone, G; Schuringa, JJ; Wong, B, 2005) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 6 (100.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Nordigården, A | 1 |
| Kraft, M | 1 |
| Eliasson, P | 1 |
| Labi, V | 1 |
| Lam, EW | 1 |
| Villunger, A | 1 |
| Jönsson, JI | 1 |
| Chung, KY | 1 |
| Morrone, G | 1 |
| Schuringa, JJ | 1 |
| Wong, B | 1 |
| Dorn, DC | 1 |
| Moore, MA | 1 |
| Mony, U | 1 |
| Jawad, M | 1 |
| Seedhouse, C | 1 |
| Russell, N | 1 |
| Pallis, M | 1 |
| Torres, LA | 1 |
| Barbarroja, N | 1 |
| Dorado, G | 1 |
| Velasco, F | 1 |
| López-Pedrera, C | 1 |
| Tse, KF | 1 |
| Allebach, J | 1 |
| Levis, M | 1 |
| Smith, BD | 1 |
| Bohmer, FD | 1 |
| Small, D | 1 |
| Takahashi, S | 1 |
| Harigae, H | 1 |
| Yokoyama, H | 1 |
| Ishikawa, I | 1 |
| Abe, S | 1 |
| Imaizumi, M | 1 |
| Sasaki, T | 1 |
| Kaku, M | 1 |
1 trial available for ag-1296 and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
Synergistic effect of arsenic trioxide and flt3 inhibition on cells with flt3 internal tandem duplication.
Topics: Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Apoptosis; Arsenic Trioxide; | 2006 |
5 other studies available for ag-1296 and Acute Myelogenous Leukemia
| Article | Year |
|---|---|
BH3-only protein Bim more critical than Puma in tyrosine kinase inhibitor-induced apoptosis of human leukemic cells and transduced hematopoietic progenitors carrying oncogenic FLT3.
Topics: Animals; Apoptosis; Apoptosis Regulatory Proteins; Bcl-2-Like Protein 11; Blotting, Western; Cell Li | 2009 |
Enforced expression of an Flt3 internal tandem duplication in human CD34+ cells confers properties of self-renewal and enhanced erythropoiesis.
Topics: Animals; Antigens, CD34; Cell Proliferation; Cells, Cultured; DNA-Binding Proteins; Erythropoiesis; | 2005 |
Resistance to FLT3 inhibition in an in vitro model of primary AML cells with a stem cell phenotype in a defined microenvironment.
Topics: ADP-ribosyl Cyclase 1; Antigens, CD34; Cell Line, Tumor; Cell Survival; Cytarabine; Drug Resistance, | 2008 |
VEGF/KDR loop is a target of AG1296 in acute myeloid leukaemia showing FLT3-internal tandem duplications.
Topics: Antineoplastic Agents; Cell Line, Tumor; Humans; Leukemia, Myeloid, Acute; Membrane Proteins; Tandem | 2009 |
Inhibition of the transforming activity of FLT3 internal tandem duplication mutants from AML patients by a tyrosine kinase inhibitor.
Topics: Amino Acid Sequence; Apoptosis; Base Sequence; Cell Line; Cloning, Molecular; DNA Primers; Down-Regu | 2002 |